G1 Therapeutics, Inc.【GTHX】 業績推移・財務諸表

(単位:千ドル) 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 1Q24 2Q24
売上高 - - - - - - - - - - - - 2,140 26,599 16,546 14,218 6,604 4,858 5,796 6,902 10,573 23,576 10,250 12,946 42,392 12,300 14,476 16,546
売上成長率(%) - - - - - - - - - - - - - - - -
研究開発費 13,667 14,054 - 17,347 18,385 15,873 - 18,080 23,489 22,941 - 20,434 18,531 17,932 - 16,540 18,752 21,143 - 26,305 20,843 19,581 - 15,480 12,040 8,811 7,318 5,738
販売管理費 - - - - - - - - - - - - - - - 22,970 25,236 24,268 - 26,709 25,716 24,432 - 21,753 17,432 16,781 15,127 13,610
営業費用 15,379 15,929 17,282 20,725 21,653 20,822 26,086 25,881 32,583 34,024 36,553 31,821 32,962 36,344 40,634 39,753 44,796 46,002 43,382 53,683 47,535 45,124 41,137 38,692 30,876 28,668 23,524 20,081
営業利益 -15,379 -15,929 -17,282 -20,725 -21,653 -20,822 -26,086 -25,881 -32,583 -34,024 -36,553 -31,821 -30,822 -9,745 -24,088 -25,535 -38,192 -41,144 -37,586 -46,781 -36,962 -21,548 -30,887 -25,746 11,516 -16,368 -9,048 -3,535
営業利益率 (%) - - - - - - - - - - - -
経常(税引前)利益 - - - - - - - - - - - - - -10,743 -24,868 -26,304 -39,202 -42,147 -39,774 -49,192 -39,446 -24,053 -33,168 -27,595 10,018 -17,299 -10,219 -5,469
経常(税引前)利益率(%) - - - - - - - - - - - - - -40.39 -150.3 -185.0 -593.61 -867.58 -686.23 -712.72 -373.08 -102.02 -323.59 -213.15 23.63 -140.64 -70.59 -33.05
法人税等合計 - - - - - - - - - - - - - 931 479 138 220 321 246 - - 1,200 481 - 1,308 905 - -
実効税率(%) - - - - - - - - - - - - - - - - - -
純利益 -15,194 -15,601 -16,981 -20,410 -20,868 -19,918 -24,092 -23,952 -30,690 -32,364 -35,441 -31,023 -31,210 -11,674 -25,347 -26,442 -39,422 -42,468 -40,020 -49,192 -39,446 -25,272 -33,649 -27,595 8,710 -18,204 -10,219 -5,469
純利益率(%) - - - - - - - - - - - -
一株あたり利益 - - - - - - - - - - - - - - - - - - - - -0.92 -0.59 -0.73 -0.53 0.17 -0.35 -0.2 -0.1
希薄化後一株あたり利益 - - - - - - - - - - - - - - - - - - - - -0.92 -0.59 -0.73 -0.53 0.14 -0.35 -0.2 -0.1
EBITDA - - - - - - - - - - - - - - - - - - - - -
EBITDAマージン(%) - - - - - - - - - - - - - - - - - - - - - - - -